Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography

Vox Sanguinis

Volumn 84, Issue 3, 2003, Pages 193-201

  Lebing, Wytold ^a   Remington, K M ^a   Schreiner, C ^a   Paul, H I ^b  

^a BAYER CORPORATION   (United States)

^b BAYER AG   (Germany)

Author keywords

Caprylate; Chromatography; Gamunex ; IgG subclass; IVIG; Viral safety

Indexed keywords

ALBUMIN; DETERGENT; GLYCINE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; OCTANOIC ACID; SOLVENT;

ANIMAL EXPERIMENT; ANION EXCHANGE; ANTIBODY RESPONSE; ARTICLE; COLUMN CHROMATOGRAPHY; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PURITY; DRUG SAFETY; FEMALE; MOUSE; NONHUMAN; OPSONIZATION; PH; PRECIPITATION; PRIORITY JOURNAL; VIRUS INACTIVATION;

ANIMALS; BACTERIAL INFECTIONS; CHROMATOGRAPHY; DISINFECTION; DRUG CONTAMINATION; DRUG INDUSTRY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MICE; OCTANOIC ACIDS; PRECIPITATION; SURVIVAL RATE; VIRUS DISEASES; VIRUSES;

EID: 0242669192     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2003.00285.x     Document Type: Article

References (47)

1. Cohn EJ, Strong LE, Hughes WL Jr, Mulford DJ, Ashworth JN, Melin M, Taylor HL: Preparation and properties of serum and plasma proteins III. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946; 68:459-475
2. Oncley JL, Melin M, Richert DA, Cameron JW, Gross PM Jr: The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta-lipoprotein into subfractions of human plasma. J Am Chem Soc 1949; 71:541-550
3. Finlayson JS: History of immunoglobulin use; in Alving BM, Finlayson JS (eds): Immunoglobulins: Characteristics and Uses of Intravenous Preparations. Washington, US Government Printing Office, 1980:173-177
4. Bruton O: Agammaglobulinemia. Pediatrics 1952; 9:722-728
5. Janeway CA, Apt L, Gitlin D: Agammaglobulinemia. Trans Assoc Am Physicians 1953; 66:200
6. Barandun S, Kistler P, Jeunet F, Isliker H: Intravenous administration of human gamma globulin. Vox Sang 1962; 7:157-174
7. Schultze HE, Schwick G: Uber neue Möglichkeiten intravenöser Gammaglobulin-Applikation. Deuthsche Med Wchnschr 1962; 87:1643-1650
8. Sgouris JT: The preparation of plasmin treated immune serum globulin for intravenous use. Vox Sang 1967; 13:71-84
9. Stephan W: Undegraded human immunoglobulin for intravenous use. Vox Sang 1975; 28:422-437
10. Masuho Y, Tomibe S, Matzawa K, Ohtsu A: Development of an intravenous gamma-globulin with Fc activities I. Preparation and characterization of S-sulfonated human gamma globulin. Vox Sang 1977; 32:175-181
11. Barandun S, Morell A, Skavril F: Clinical experience with immunoglobulin for intravenous use; in Alving BM, Finlayson JS (eds): Immunoglobulins: Characteristics and Uses of Intravenous Preparations. Washington, US Government Printing Office, 1980:31-35
12. Schroeder DD, Tankersley DL, Lundblad JL: A new preparation of modified immune serum globulin (human) suitable for intravenous administration. I. Standardization of the reduction and alkylation reaction. Vox Sang 1981; 40:373-382
13. Schroeder DD, Tankersley DL, Lundblad JL: A new preparation of modified immune serum globulin (human) suitable for intravenous administration. II. Functional characterization. Vox Sang 1981; 40:383-394
14. Pollack M: Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis 1983; 147:1090-1098
15. Kim KS, Wass CA, Kang JH, Anthony BF: Functional activities of various preparations of human intravenous immunoglobulin against type III group B streptococcus. J Infect Dis 1986; 153:1092-1097
16. Bender S, Hetherington S: Haemophilus influenzae type b opsonins of intravenous immunoglobulins. J Clin Immunol 1987; 7:475-480
17. van Furth R, Braat AG, Leijh PC, Gardi A: Opsonic and physico-chemical characteristics of intravenous immunoglobulin preparations. Vox Sang 1987; 53:70-75
18. Zaia JA: Pathogenesis of cytomegalovirus-associated immunopathology, implication for immunoglobulin production and evaluation; in Morell A, Nydeggar U (eds): Clinical Use of Intravenous Immunoglobulin. London, Academic Press, 1986:299-313
19. Janeway CA, Merler E, Rosen FS, Salmon S, Crain JD: Metabolism of gamma globulin fragments in normal and agammaglobulinemic persons. N Engl J Med 1968; 278:919-923
20. Winston DJ, Ho WG, Rasmussen LE, Lin CH, Chu CL, Merigan TC, Gale RP: Use of intravenous immune globulin in patients receiving bone marrow transplants. J Clin Immunol 1982; 2 (April Suppl.):42S-47S
21. Hagenbeek A, Brummelhuis GJ, Donkers A, Dumas AM, ten Haaft A, Schaap BJP, Sizoo W, Lowenberg B: Rapid clearance of cytomegalovirus-specific IgG after repeated intravenous infusions of human immunoglobulin into allogeneic bone marrow transplant recipients. J Infect Dis 1987; 155:897-902
22. Hooper JA, Mankarious S, Liu-Rash CR: Stabilized gamma globulin concentrate. US Patent No. 4,439,421, 1984
23. McCue JP, Hein RH, Tenold R: Three generations of immunoglobulin G preparations for clinical use. Rev Infect Dis 1986; 8:S374-S381
24. Mitra G, Wong MF, Mozen MM, McDougal JS, Levy JA: Elimination of infectious retroviruses during preparation of immunoglobulins. Transfusion 1986; 26:394-397
25. Louie RE, Galloway CJ, Dumas ML, Wong MF, Mitra G: Inactivation of hepatitis C virus in low pH intravenous immunoglobulin. Biologicals 1994; 22:13-19
26. Center for Disease Control and Prevention: Outbreak of hepatitis C associated with intravenous immunoglobulin administration, United States, October 1993-June 1994. Morb Mortal Wkly Rep 1993; 43:505-509
27. Lundblad JL, Seng RL: Inactivation of lipid-enveloped viruses in proteins by caprylate. Vox Sang 1991; 60:75-81
28. Slingsby RW: Gradient elution of aliphatic carboxylic acids by ion chromatography in the ion-suppression mode. J Chromatogr 1986; 371:373-382
29. Alving BM, Tankersley DL, Mason BL, Rossi F, Aronson DL, Finlayson JS: Contact-activated factors: contaminants of immunoglobulins preparations with coagulant and vasoactive properties. J Lab Clin Med 1980; 96:334-346
30. Mayer MM: Quantitative complement fixation analysis; in Kabat EA, Mayer MM (eds): Experimental Immunochemistry. Springfield, Thomas 1961:227-218
31. Section H: Viral, rickettsial, and chlamydial immunology; in Rose NR, Friedman H, Fahey JL (eds): Manual of Clinical Laboratory Immunology. Washington, DC, American Society for Microbiology 1986:488-599
32. Gupta RK, Higham S, Gupta CK, Rost B, Siber GR: Suitability of the Vero cell method for titration of diphtheria antitoxin in the United States potency test for diphtheria toxoid. Biologicals 1994; 22:65-72
33. Widman F, eds. Technical Manual of the American Association of Blood Banks, edn 9. Arlington, American Association of Blood Banks, 1985
34. Trejo SR, Hotta J, Lebing W, Stenland C, Evans Storms R, Lee DC, Li H, Petteway S, Remington KM: Evaluation of virus and prion reduction in a new intravenous immunoglobulin (IGIV) manufacturing process. Vox Sang 2003; 84:176-187
35. Korneyeva M, Hotta J, Lebing W, Rosenthal RS, Franks L, Petteway SR Jr: Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates. Biologicals 2002; 30:153-162
36. Cavalli-Sforza L: Biometrie Grundzuge Biologischmedizinischer Statistik [Biometry, the Basics of Biological and Medical Statistics]. Stuttgart, Gustav Fischer Verlag, 1974
37. Lee DC, Stenland CJ, Hartwell RC, Ford EK, Cai K, Miller JL, Gilligan KJ, Rubenstein R, Fournel M, Petteway SR Jr: Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Methods 2000; 84:77-89
38. Lee DC, Stenland CJ, Miller JL, Cai K, Ford EK, Gilligan KJ, Hartwell RC, Terry JC, Rubenstein R, Fournel M, Petteway SR Jr: A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2001; 41:449-455
39. Schroeder DD, Mozen MM: Australia antigen: distribution during Cohn ethanol fractionation of human plasma. Science 1970; 168:1462-1464
40. Yei S, Yu MW, Tankersley DL: Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion 1992; 32:824-828
41. Habeeb AF, Francis RD: Preparation of human immunoglobulin by caprylic acid precipitation. Prep Biochem 1984; 14:1-17
42. Stecher PG, Windholz M, Leahy DS, Bolton DM, Eaton LG, eds. The Merck Index, edn 8. Rahway, Merck, Inc., 1968
43. Gellis SS, Neefe JR, Stokes J Jr, Strong LE, Janeway CA, Scatchard G: Chemical, clinical and immunological studies on the products of human plasma fractionation. XXXVI. Inactivation of the virus of homologous serum hepatitis in the solutions of normal human serum by means of heat. J Clin Invest 1948; 27:239-244
44. Yu MW, Finlayson JS: Stabilization of human albumin by caprylate and acetyltryptophanate. Vox Sang 1984; 47:28-40
45. Hollinger FB: Hepatitis B virus; in Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TM, Roizman B, Strauss SE (eds): Fields Virology. Philadelphia, Lippincott-Raven, 1996:2739-2807
46. Ballow M, Berger M, Bonilla F, Buckley R, Cunningham-Rundles C, Fireman P, Kaliner M, Ochs H, Skoda-Smith S, Sweetser M, Taki H, Lathia C: Pharmacokinetics of a novel, intravenous immunoglobulin preparation. J Allergy Clin Immunol 2001; 107:a685
47. Ballow M, Berger M, Bonilla F, Buckley R, Cunningham-Rundles C, Fireman P, Kaliner M, Ochs H, Skoda-Smith S, Sweetser M, Taki H, Lathia C: Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex 10%). Vox Sang 2003; 84:202-210